*Corresponding author:Gabor Mikala, Department of Haematology and Stem Cell Transplantation South-Pest Central Hospital, National Institute for Haematology and Infectious Diseases, Budapest, Hungary, H-1097
Received: May 11, 2018; Published: May 18,2018
To view the Full Article Peer-reviewed Article PDF
Multiple myeloma is the second most common haematological malignancy – though multiple effective therapeutic options exist for disease control – cure of myeloma still remains the exception. Our present therapeutic approach is founded on apoptosis induction in tumor cells by various different stimuli, most commonly by DNA damage, oxidative or endoplasmic reticular (proteomic) stress. Effective treatment of relapsed and/or refractory disease rarely provides long term disease control mainly due to development of resistance to pharmacological induction of apoptosis pathways.